Menopause hormone therapy: latest developments and clinical practice

Menopause hormone therapy (MHT) is the most efficient treatment for symptoms of acute climacteric syndrome and for efficient prevention of long-term estrogen deficiency. Vaginal administration of low doses of estrogen is a therapy of choice for treatment and prevention of urogenital atrophy and its...

Full description

Saved in:
Bibliographic Details
Published inDrugs in Context Vol. 8; pp. 212551 - 9
Main Author Fait, Tomas
Format Journal Article
LanguageEnglish
Published England BioExcel Publishing Ltd 2019
Subjects
atrophic vaginitis
bazedoxifene
climacteric syndrome
menopause hormone therapy
phytoestrogens
Review
tibolone
atrophic vaginitis
bazedoxifene
phytoestrogens
tibolone
climacteric syndrome
menopause hormone therapy
Online AccessGet full text
ISSN1745-1981
1740-4398
1740-4398
DOI10.7573/dic.212551

Cover

More Information
Summary:Menopause hormone therapy (MHT) is the most efficient treatment for symptoms of acute climacteric syndrome and for efficient prevention of long-term estrogen deficiency. Vaginal administration of low doses of estrogen is a therapy of choice for treatment and prevention of urogenital atrophy and its consequences. Systemic treatment may include estrogen, but an equally efficient alternative is tibolone. Nonhormonal therapy relies on phytoestrogens, black cohosh extract, and serotonin reuptake inhibitors.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1745-1981
1740-4398
1740-4398
DOI:10.7573/dic.212551